Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment

Abstract Background: PLK1 overexpression is oncogenic and is associated with poor prognosis in various cancers. However, the current PLK1 inhibitors have achieved limited clinical successes. On the other hand, although immunotherapies are demonstrating efficacy in treating many refractory cancers, a substantial number of patients do not respond to such therapies. The potential of combining PLK1 inhibition with immunotherapy for cancer treatment is worthy of exploration. Methods: We analyzed the associations of PLK1 expression with tumor immunity in 33 different cancer